Contraindications. Hypophosphataemia (aluminium), severe kidney impairment (magnesium and aluminium), hypercalcaemia (calcium), heart failure or hypertension (sodium-rich forms).
Adverse effects. Constipation or diarrhoea; hypermagnesaemia and aluminium accumulation in kidney impairment (encephalopathy, osteomalacia, microcytic anaemia); hypophosphataemia with prolonged aluminium use; milk-alkali syndrome (hypercalcaemia, alkalosis, kidney injury) with excess calcium carbonate.
Interactions. Chelation or raised gastric pH reduces absorption of fluoroquinolones, tetracyclines, levothyroxine, iron, bisphosphonates, itraconazole, atazanavir and rilpivirine. Separate by at least 2 hours; give a fluoroquinolone at least 2 hours before or 6 hours after. Dolutegravir should be taken 2 hours before or 6 hours after any antacid containing aluminium, magnesium or calcium; this matters in people on antiretroviral therapy who self-medicate.
Special groups.
- Pregnancy: calcium and alginate products acceptable; avoid sodium bicarbonate and long-term magnesium trisilicate.
- Breastfeeding: acceptable.
- Children: use only product-specific doses.
- Older adults and kidney impairment: avoid regular aluminium or magnesium.
Monitoring. Calcium, phosphate and magnesium with regular or high-dose use; serum aluminium in dialysis patients.
Referral and escalation. Dysphagia, weight loss, bleeding, anaemia, persistent vomiting, or new dyspepsia over 55 need endoscopy.